A carregar...
Filgotinib: First Approval
Filgotinib (Jyseleca(®)) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Sciences for the treatment of inflammatory autoimmune diseases, including inflammatory arthritis and inflammatory bowel disease. The JAK-STAT signalling pat...
Na minha lista:
| Publicado no: | Drugs |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7858213/ https://ncbi.nlm.nih.gov/pubmed/33237566 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01439-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|